Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Eli Lilly and AstraZeneca (AZ) have said they are to co-develop a potentially disease-modifying treatment for Alzheimer's disease (AD), in the aftermath of the high-profile failure of a Lilly ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

which accumulates in the brains of Alzheimer's patients. The two drugs ‒ Eli Lilly's Kisunla and Eisai and Biogen's drug Leqembi ‒ include warnings for MRI-visible injuries called amyloid ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership. Read more about LLY stock here.

19 Apr 2025 04:23:12 GMT Eli Lilly and Company (LLY) shares rocketed 11.74% Monday after the Indianapolis-based drug manufacturer said its experimental Alzheimer’s drug significantly slowed the ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

April 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month ...